Bayer AG ADR

There's no telling if stocks have bottomed, but selling losing positions can help you find a silver lining in a down market.

An ESG frame helps us bring a better look at valuation within the healthcare sector.

Morningstar and Sustainalytics offer complementary methodologies.

Recent results from some of the most undervalued large drugmakers we cover.

We see long-term potential for this wide-moat seed and chemical producer.

We expect solid results but will be listening for what a reduction in rebating means for sales growth at various firms, among other trends.

Even with the recent glyphosate loss, scientific studies still support the product.

Here are some of our analysts' best ideas across sectors.

Drug manufacturers and healthcare providers offer the most upside.

We expect appeals to delay any impact but revoking the ACA would likely create the most pressure for the healthcare services companies.

While we believe the restructuring makes strategic sense, the related one-time costs are higher than we expected.

Damien Conover expects to see fewer major changes to U.S. healthcare policy, and he offers some picks for investors.

Advisors find that sustainable investing is good for business.

Investors can find plenty of low-carbon options among our medalists.

Last month one stock joined the wide-moat club while four others achieved narrow-moat status.

A focus on unmet medical needs is helping pharma firms maintain their competitive advantage.

These constituents of the Morningstar Global ex-US Moat Focus Index are trading at steep discounts to our fair value estimates.

The market reaction to glyphosate's legal issues looks overdone.

Several funds take a dive into GE as industrials receive some attention this quarter along with General Motors.

Litigation concerns about glyphosate weedkillers are weighing on Bayer's shares, but we don't expect to make a significant change to our fair value estimate.